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The clinical phenotype of congenital disorders of glycosylation is heterogeneous, mostly including a severe neuro-
logical involvement and multisystem disease. We identified a novel patient with a galactosyltransferase deficiency
with mild hepatopathy and coagulation anomalies, but normal psychomotor development. The tissue-specific
expression of the defective B4GALT1 gene correlated with the clinical phenotype. (J Pediatr 2011;159:1041-3)From the Department of Laboratory Medicine (M.G., J.dR., L.vdH., R.W., D.L.),
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ongenital disorders of glycosylation (CDG) represent
a large and rapidly growing family of genetic diseases
with abnormal glycosylation of proteins, abnormal
glycosylation of lipids, or both.1 In general, CDG presents
as multi-system disorder because of the ubiquitous expres-
sion of the glycosylation genes. Neurologic involvement is
frequent in both CDG-I and CDG-II, and several CDG-II de-
fects show distinct neurologic symptoms such as COG7-
CDG2 and ATP6V0A2-CDG.3 Additional features in patients
with CDG-II include hematologic and hepatic involvement,
epilepsy, ataxia, coagulation problems, and dysmorphic fea-
tures. A growing group of patients with CDG-II, with a wide
range of clinical symptoms, have an unsolved genetic etiol-
ogy.4 Although certain defects occur relatively frequently
(PMM2-CDG or ALG6-CDG), other CDG subtypes have
been described in single cases (B4GALT1-CDG, DPM3-
CDG), which hampers gene identification on basis of clinical
symptoms.
In this paper, we present a tissue-restricted CDG type II
defect with an exceptionally benign clinical presentation
without neurological involvement.
Clinical Phenotype
Patient 1 was born at term, with age-appropriate growth
measures. She was examined for recurrent episodes of diar-
rhea and mild hepatomegaly (Table I). A transient axial
hypotonia improved within the first year of life. At age
7 years, she had normal growth and psychomotor
development and attended regular school. She had
dysmorphic facial features involving hypertelorism, broad
nasal bridge, full supra-orbital region, a long philtrum, thin
upper lip, low-set ears, and severe myopia (5 D). With
laboratory investigations, abnormal liver test results,
abnormal coagulation, and borderline low platelets wereCDG Congenital disorders of glycosylation
SNP Single nucleotide polymorphismshown (Table I). Galactosemia was ruled out. At the age of
9 years, she had normal intelligence and completely normal
motor performance, including muscle tone and strength,
coordination, and deep tendon reflexes.
Patient 2 was reported earlier as having B4GALT1-CDG.5,6
Severe perinatal complications occurred because of bleeding
diathesis. With laboratory investigation, abnormal liver test
results, increased levels of creatine kinase, abnormal coagula-
tion, and thrombocytopenia were shown. Hydrocephalus
caused by a Dandy-Walker malformation developed, requir-
ing shunt placement. Mild dysmorphic facial features includ-
ing low-set ears and a broad nose were present. Since the
original description of this patient in 2002, his growth curve
and psychomotor development normalized. At the age of 11
years, he had no hepatomegaly, diarrhea, or significant neu-
rological symptoms or mental retardation.
Biochemical and Genetic Investigations
Detailed information on biochemical and genetic methods is
provided in the Appendix (available at www.jpeds.com).
Screening for CDG with transferrin isofocusing consistently
showed an abnormal type 2 pattern (Figure, A). Results of
apolipoprotein C-III isofocusing for analysis of mucin O-
glycosylation defects were normal (data not shown). Plasma
N-glycan profiling with mass spectrometry (Figure, B) in
control subjects7 shows fully synthesized N-glycans (such as
m/z 2794 and 3606) and lower amounts of the non-
completed N-glycans (m/z 2433). In patient 1, the profileGermany (J.P.); and Department of Human Genetics, University of Miami Miller
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Table I. Clinical features and laboratory findings
Clinical features Patient 1* Patient 2* Remarks
Perinatal bleeding diathesis  + Recurrent
Axial hypotonia + + Transient
Dandy-Walker malformation  +
Dysmorphic facial features + +
Hepatomegaly + 
Episodes of diarrhea +  Recurrent
Growth retardation  
Myopia + +






Antithrombin III (%) 52 33 80-120
Protein C (%) 40 45 70-140
Protein S (%) 41 46 70-140
Platelets ( 109/L) 120 139 120-350
Creatine kinase (IU/L) 320 573 <290
Aspartate aminotransferase (IU/L) 216 270 10-46
*Turkish ancestry.
†The results show the most abnormal values in the course of disease.
Figure. A, Serum transferrin isoelectric focusing profiles, digits o
glycans. C, control; PMM2/MGAT2, CDG-Ia and CDG-IIa defec
matrix-assisted laser desorption ionisation-MS profile of serum
glucosamine,C =mannose,B = galactose,= = fucose,A = s
acetyl-b-D-glucosamine in fibroblasts from control subjects (1-4
andB4GALT2 in different human fetal and adult tissues. Relative ex
the tissue or area with the lowest expression level. All fetal tissues
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1042was dominated by glycans lacking galactose moieties (such as
m/z 1663, 1838, 2083); >80% of the glycans terminate in
N-acetylglucosamine as opposed to 15% in control subjects.
Galactosyltransferase activity in patient fibroblasts was
decreased to 5% (Figure, C) in control subjects, comparable
with B4GALT1-deficient patient 2.
250K single nucleotide polymorphism (SNP) array
showed a large homozygous stretch on chromosome 9, in-
cluding the B4GALT1 gene, which encodes UDP-Gal:N-ace-
tylglucosamine b-1,4-galactosyltransferase I (B4GALT1; EC
2.4.1.22). A homozygous insertion in exon 5 was identified
(c.1031-1032insC), heterozygous in both parents. The muta-
tion is identical to the previously described mutation in pa-
tient 2,5 leading to a premature stop codon with loss of the
50 C-terminal amino acids. To find an explanation for the
tissue-restricted phenotype, expression analysis was per-
formed of the B4GALT1 and B4GALT2 genes in human adult
and fetal tissues (Figure, D). Additional information are
presented in the Appendix and Table II (available at www.
jpeds.com). B4GALT1 was widely expressed in all tissues,n the left show the total number of sialic acids on transferrin
ts; patient 1 and 2, CDG type 2 profiles of both patients. B,
N-glycans of a control subjects and patient 1.- = N-acetyl
ialic acid. C, Transfer of UDP[3H]-Gal to Para-nitrophenyl-N-
), patient 1 (5), and patient 2 (6). D, Expression of B4GALT1
pression levels are given as the fold change in comparisonwith
are from 20- or 21-week-old embryos after gestation.
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December 2011 CLINICAL AND LABORATORY OBSERVATIONSwith the exception of the fetal heart and brain and adult
brain. In contrast, B4GALT2 is very specifically expressed in
fetal skeletal muscle, fetal brain, adult heart, and adult brain.
Discussion
We identified a novel patient with a CDG-II and c.1031-
1032insC mutation in B4GALT1, with a mild hepatopathy,
recurrent episodes of diarrhea, and coagulation abnormali-
ties without neurological involvement. The previously
reported patient (patient 2) with an identical mutation5
showed progressive hydrocephalus because of a Dandy-
Walker malformation, hypotonia, elevated creatine kinase
levels, and a transient cholestatic syndrome. After shunt
positioning and extensive rehabilitation, he had a benign
neurological course. At 11 years, he had normal cognitive
development, and his motor performance was only slightly
abnormal. The common features of the children are dysmor-
phic features, hypotonia, and laboratory findings of dis-
turbed coagulation factors, and abnormal liver enzymes.
Dandy-Walker malformation is a relatively common con-
genital anomaly that can be associated with numerous other
malformations of the brain and extra-cranial abnormalities,
whether or not in the context of specific syndromes. When
not diagnosed with prenatal ultrasound scanning, the
Dandy-Walker malformation generally presents with head
enlargement in the first year of life. Its enormously heteroge-
neous origin might explain its equally variable prognosis:
patients may sustain severe neurological deficits, despite early
and correct neurosurgical management. However, as many as
half the patients are reported to have normal cognitive devel-
opment.
The 7 known b-1,4-galactosyltransferases differ in kinetics,
tissue expression, and oligosaccharide acceptor specificity.8
B4GALT1 and B4GALT2 are considered most important in
galactosylation of N-glycans.9 B4GALT1 mouse knock-out
models10 were mainly characterized by growth retardation
and early death. There was no evidence for neurological
deficits. Other symptoms, including transient skin lesions
or puffy faces and pituitary insufficiency, were not observed
in our patients. Abnormal villi and enhanced proliferation of
epithelial cells were observed in the small intestine of these
mice, which may correlate with the diarrhea in patient 1. In
contrast, B4GALT2 knock-out mice showed motor-
learning retardation and impaired motor coordination.11
Our expression data indicate brain-specific expression of
B4GALT2, in which the expression of B4GALT1 is low.
This is in line with the absence of neurological symptoms
in our novel B4GALT1-CDG patient.B4GALT1-Congenital Disorders of Glycosylation Presents as a N
Hepatointestinal InvolvementIn this study, we describe the phenotype of B4GALT1-
CDG including inherited coagulation disturbances with
hepatopathy, mild hypotonia, and dysmorphic facial fea-
tures and a variable presentation of diarrhea, hepatomegaly,
and myopia. We propose to screen patients for CDG who
have mild gastrointestinal symptoms, bleeding disorders,
or both with hepatopathy, also in the absence of neurologic
symptoms. n
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Appendix
Plasma samples were collected from EDTA or heparin blood
with centrifugation and stored at20C. Unless stated other-
wise, chemical reagents were acquired from Sigma Aldrich
(St Louis, Missouri). Isoelectric focusing of serum transferrin
and apolipoprotein C-III was performed essentially as
described.1,2 Presence of sialidase in plasma as a secondary
cause of undersialylation, as seen in patients with hemolytic
uremic syndrome with a similar transferrin isoelectric focus-
ing profile, was excluded in patient 1. Plasma N-glycan pro-
filing of both patients was performed with matrix-assisted
laser desorption ionisation-linear ion trap mass spectrometry
as described,1 with 10 mL of serum.
Galactosyltransferase activity was measured in fibroblast
homogenates with UDP-[3H]Gal as donor and p-nitro-
phenyl-N-acetyl-b-D-glucosamine as acceptor, by using
a procedure modified from literature.3 To a pellet of 10 mil-
lion fibroblasts, 75 mL lysis buffer was added (0.05% v/v
Triton X-100, 150 mM NaCl and protease inhibitor [Roche
Diagnostics, Basel, Switzerland]) in 50 mM Tris-HCl pH
8.8) before 3 rounds of sonication (10 seconds, on ice). Pro-
tein concentration was determined with 2D Quant (GE
Healthcare, Buckinghamshire, United Kingdom). Galacto-
syltransferase activity was measured by incubating 3 mg of
proteins from the cell homogenate with 20 mL buffer A (10
mM Tris-HCl pH 7.7, 250 mM sucrose, 0.5% v/v Triton
X-100, 1 mM EDTA) and 30 mL buffer B (5.2 mL 0.5 M Tris-
HCl (pH 7.4), 1.5 mL Triton X-100, 4.4 mL 0.2 M MnCl2,
15.4 mL H2O, 2.5 mL 1 M p-nitrophenyl-N-acetyl-b-D-glu-
cosamine in H2O, 0.44 mL 0.2 M ATP, 0.25 mL 1 mM
UDP-galactose, 0.22 mL 0.2 mCi/mL UDP-[3H]Gal (American
Radiolabeled Chemicals, St Louis, Missouri) for 2 hours at
37C. After addition of 500 mL ultrapure water, the reaction
volume was purified on Sep-Pak Vac C18 cartridges (Waters,
Milford, Massachusetts). The cartridge was washed with 5
mL ultrapure water before elution with 2 mL 10% aqueous
methanol. 900 mL of eluent was dissolved in 10 mL Ultima
Gold XR counting fluid (Perkin Elmer, Waltham, Massachu-
setts), and the incorporated radioactive galactose was
counted in the Liquid Scintillation Analyzer Tricarb
2810TR (Perkin Elmer). After substraction of blancs (identi-
cal procedure without protein from cell homogenate), the
data were expressed as fmol UDP-[3H]Gal incorporated
per mg protein per minute.
Genomic DNA was extracted and genotyped with Affyme-
trix Genome-Wide Human SNP 250K Nsp1 arrays. Copy
number analysis and exporting of SNPs were performed on
the raw data using the Affymetrix Genotyping Console 3.0.
Homozygosity mapping on a 250K SNP array was performed
on the genomes of patient 1, her parents, and a healthy sibling
to restrict the number of candidate genes for mutation anal-
ysis. The genotyped SNPs were analyzed for homozygous
stretches with in house algorithms. The longest homozygous
stretch, not homozygous in parents or unaffected sibling, was
detected on chromosome 9, spanning 63 Mb from 9p21.1 to
9q22.32 and included the B4GALT1 gene, which encodes
UDP-Gal:N-acetylglucosamine b-1,4-galactosyltransferase I
(B4GALT1; EC 2.4.1.22). B4GALT1 is a 6-exon gene located
on chromosome 9p13, encoding a 398 amino acid protein.
DNA analysis was performed on genomic DNA. The
B4GALT1 gene (ENST00000379731) was amplified in 6 frag-
ments (exon 1-6). Fragments included both DNA sequences
of the individual exons and splice donor and splice acceptor
sites. Oligonucleotide primers were designed from the
human B4GALT1 gene sequence (primer sequences are avail-
able on request). The nucleotide numbering follows comple-
mentary DNA numbering with +1 corresponding to the A of
the ATG translation codon in the reference sequence. The
initiation codon is codon 1. In DNA from 100 healthy control
individuals with similar ethnicity and in the patient’s healthy
sibling, no mutation was identified.
SYBR Green-based real-time quantitative polymerase chain
reaction expression analysis was performed on a 7500 Fast
Real-Time PCR System (Applied Biosystems, Foster City,
California) by using Power SYBR Green PCR Master Mix
(Applied Biosystems) according to themanufacturer’s instruc-
tions. Primers were developed with the primer3 program
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi)
and validated as described before.4 Primer sequences are given
inTable II.GUSB and PPIBwere used as reference genes. Total
RNA from different human adult and fetal tissues was ordered
from Stratagene Europe (Amsterdam, The Netherlands). Total
RNA was transcribed into complementary DNA by using the
iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules,
California) according to the manufacturer’s protocol.
Complementary DNA was purified by using the NucleoSpin
extract II kit (Macherey-Nagel, D€uren, Germany) according
to the manufacturer’s protocol. Quantitative polymerase
chain reaction quantifications were performed in duplicate
on the equivalent of 12.5 ng total RNA input. Experimental
threshold cycles (Ct) values were within the range of
complementary DNA dilutions used to validate the primers.
The melt curves of all polymerase chain reaction products
showed a single polymerase chain reaction product. Results
of all water controls were negative. Differences in expression
of a gene of interest in two samples were calculated by the
comparative Ct or 2DDCt method.5,6 Data are expressed
relative to the tissue with lowest expression and a Ct value
below 32, set at 1.
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Table II. Primer sequences for the quantitative polymerase chain reaction analysis of B4GALT1-2
Gene Gene ID Forward 50->30 Reverse 50->30
GUSB NM_000181.1 agagtggtgctgaggattgg ccctcatgctctagcgtgtc
PPIB NM_000942.4 cggaaagactgttccaaaaac gattacacgatggaatttgctg
B4GALT1 NM_001497.3 ctatatctcgcccaaatgctg gtgcaattcggtcaaacctc
B4GALT2 NM_001005417.1 cgcgacaagcataacgaac agacctggtaccgcactgac
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